Jyong Biotech Ltd. Ordinary Shares
NASDAQ:MENSBiotechnology
-$0.02 today
- Market cap
- $141.41M
- Beta
- 2.08
- P/E (TTM)
- -25.1
- EPS (TTM)
- -$0.06
Volume 0.07M
Average 0.10M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Jyong Biotech Ltd. Ordinary Shares
NASDAQ:MENS
Intrinsic Alpha fair value
Locked
Current Price
$1.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A — |
| Revenue | N/A | N/A | N/A | N/A — |
| Net Income | N/A | N/A | N/A | N/A — |
| EBIT | N/A | N/A | N/A | N/A — |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Apogee Therapeutics, Inc. NASDAQ:APGE | $8.40B | $135.07 | Not rated | -22.7 | +111.61% |
CG Oncology, Inc. Common stock NASDAQ:CGON | $6.65B | $74.40 | Not rated | -28.0 | +87.79% |
Centessa Pharmaceuticals plc NASDAQ:CNTA | $6.27B | $40.50 | Not rated | -24.4 | +44.64% |
Travere Therapeutics, Inc. NASDAQ:TVTX | $4.86B | $50.65 | Overvalued | -235.0 | +41.80% |
Xenon Pharmaceuticals Inc. NASDAQ:XENE | $3.98B | $40.48 | Not rated | -12.1 | -7.13% |
Legend Biotech Corporation NASDAQ:LEGN | $3.24B | $17.50 | Not rated | -21.4 | -41.96% |
Dyne Therapeutics, Inc. NASDAQ:DYN | $3.22B | $17.16 | Not rated | -7.2 | -22.96% |
Celcuity Inc. NASDAQ:CELC | $3.15B | $64.37 | Not rated | -23.7 | -41.00% |
Ultragenyx Pharmaceutical Inc. NASDAQ:RARE | $1.64B | $16.08 | Not rated | -4.6 | -44.35% |
Ascentage Pharma Group International NASDAQ:AAPG | $339.78M | $14.62 | Not rated | -8.9 | -59.59% |
Continue the stock analysis
Jump to another research area for this company.